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highest priority symptoms of patients with advanced brain tumors
on treatment, comparing patient priority ratings with those of
oncology experts, and constructing a brief symptom index using
combined input to assess these symptoms and concerns. Methods:
Fifty patients with advanced primary brain tumors and 10 physician
experts were recruited from the National Comprehensive Cancer
Network institutions and community support agencies. By using a
40-item symptom checklist, patients ﬁrst selected up to 10 of the
most important symptoms/concerns to monitor when assessing the
value of drug treatment for brain tumors, then nominated up to 5 of
the very most important concerns, and ﬁnally generated additional
symptoms/concerns. By using the same checklist as patients,
physicians rated each symptom/concern as disease- or treatment-
related. Results: By using the combined input, a 24-item National
Comprehensive Cancer Network/Functional Assessment of Cancer
Therapy-Brain Symptom Index (NFBrSI-24) was developed. The
NFBrSI-24 showed good internal consistency (α ¼ 0.84), signiﬁcantlysee front matter Copyright & 2014, International S
r Inc.
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rthwestern.edu.
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reet, 19th Floor, Chicago, IL 60061.differentiated patients with different levels of functional status
(F2,47 ¼ 8.21; P o .001), and demonstrated good convergent validity
with the Functional Assessment of Cancer Therapy-General func-
tional, physical, social, emotional, and brain tumor–speciﬁc con-
cerns (ρ ¼ 0.59, 0.57, 0.40, 0.35, and 0.50, respectively; Ps o 0.05).
Conclusions: The NFBrSI-24, an index of the symptoms in
advanced brain tumors perceived as most important by both
patients and clinicians, improves upon existing measures of brain
tumor symptoms through better satisfaction of regulatory require-
ments for measure development. The ﬁndings suggest good reli-
ability and validity, indicating that the NFBrSI-24 is a promising
brief assessment of high-priority advanced brain tumor symptoms
for research and clinical settings.
Keywords: health-related quality of life, NFBrSI-24, primary brain
tumor, symptom index.
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Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The incidence rate of primary malignant brain and central
nervous system tumors for the years 2005 to 2009 was 6.5 cases
per 100,000 and that for primary nonmalignant brain and central
nervous system tumors was 13.5 cases per 100,000 [1]. Patients
with brain tumors exhibit a wide range of symptoms depending
on various factors such as tumor location, size, degree of edema,
and histology. They can present with either acute or subacute
neurologic symptoms or a more protracted course of worsening
neurologic and cognitive symptoms [2]. The importance of
symptom control in cancer, including brain tumors, has been
widely recognized because of the extraordinarily high prevalence
of physical and psychological symptoms as well as the effect of
these symptoms on patients’ health-related quality of life
(HRQOL) [3–6]. For patients with advanced disease, in which lifeexpectancy is reduced and there is no cure, relief from symptoms
and maintenance of function become primary objectives of
medical intervention [7,8]. In evaluating the efﬁcacy of new
chemotherapeutic agents, symptom reduction or relief from
treatment may be considered a meaningful outcome [9]. Even
beyond their association with HRQOL, symptoms can predict
disease progression [2,10]. Quinten et al. [10] reviewed 30
randomized controlled trials, including brain tumor trials, from
the European Organization for Research and Treatment of Cancer
between 1986 and 2004, which included symptom and function
assessment. They found that these assessments provided sig-
niﬁcant prognostic value in addition to the sociodemographic
and clinical variables typically examined in relation to survival.
The quality of symptom reports is highly dependent on the
instruments and methods (e.g., clinician- vs. patient-report) used
to acquire the data. Most recently validated measures of cancer-ociety for Pharmacoeconomics and Outcomes Research (ISPOR).
al Sciences, Northwestern University Feinberg School of Medicine,
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symptoms, such as pain and fatigue, within a broader multi-
dimensional HRQOL assessment [4,11–13]. Disease-speciﬁc meas-
ures offer the advantages of being more likely to be sensitive to
the effect of speciﬁc tumor types and associated treatments [14],
underscoring the importance of developing tumor-speciﬁc symp-
tom lists, as opposed to generic symptom lists, to assess drug
efﬁcacy across the broad spectrum of tumors. Only a few existing
symptom instruments are speciﬁc to brain tumors (e.g., Functional
Assessment of Cancer Therapy–Brain Tumor [FACT-Br] [15], M.D.
Anderson Symptom Inventory for Brain Tumor [16], and European
Organization for Research and Treatment of Cancer Brain Cancer
Module [17]), and the item stems and rating scales vary widely
even between these measures, highlighting the need for improved
measures of symptoms speciﬁc to advanced brain tumors.
Two prerequisites to constructing symptom lists for evaluating
response to chemotherapy in advanced cancer are as follows: 1)
information from patients on their perceptions of the most
important symptoms related to treatment and 2) input from
clinicians on the prevalence, relative importance, and likely
attribution (disease-related or treatment-related) of the array of
symptoms and concerns associated with brain tumors. We have
completed important groundwork toward fulﬁlling these prereq-
uisites. Before the work reported here, we completed semi-
structured interviews with patients and providers to gather input
about brain tumor–speciﬁc concerns, resulting in the development
of the 40-item FACT-Br, a measure of brain tumor–speciﬁc HRQOL
[15]. Next, we completed a comprehensive survey of physician
and nurse experts at 17 National Comprehensive Cancer Network
(NCCN) member institutions, which provided detailed information
on the priority symptoms endorsed by oncology experts for nine
tumor sites, including brain tumors [18]. In this previous work, we
demonstrated that experts in the management of brain tumors
hold similar views about the symptoms that are most important
to monitor when treating patients and that are applicable to the
assessment of drug efﬁcacy. Furthermore, we have shown that
almost all the symptoms identiﬁed by experts as the most
important to assess in treating patients with brain tumors can
be derived from a well-established multidimensional HRQOL
questionnaire, Functional Assessment of Chronic Illness Therapy
(FACIT) measurement system [13]. Patient ratings of symptom
relevance and severity of symptoms and concerns, however,
especially in the psychological realm, may differ from those of
providers [19–22]. The Food and Drug Administration (FDA)
presents a similar observation and guidance [23], that deﬁnitions
of meaningful symptom outcomes should include patient-derived
deﬁnitions including cognitive interviewing and carefully
designed patient-reported outcome measures. When designed in
accordance to the FDA guidance, such measures are more likely to
be compelling end points eligible for use in registration trials
presented to the FDA, and studies seeking to satisfy regulatory
requirements for a standardized tool to evaluate drug efﬁcacy
with respect to symptomatology [24]. In response, the primary
goals of this study were to identify the highest priority symptoms
of patients with advanced brain tumors, to compare patients’
priority ratings with those of oncology experts, and to construct a
brief symptom index using the combined input (i.e., physicians,
nurses, and patients) to assess these symptoms and concerns.Methods
Sample
Patient eligibility and recruitment
Patients were eligible for the study if they were at least 18 years
old and had a diagnosis of a grade III or IV brain tumor.Additional inclusion criteria were experience with chemotherapy
for at least two cycles (1 month for noncyclical chemotherapy);
no other primary malignancy diagnosed and/or treated within
the previous 5 years except nonmelanoma skin cancer; able to
understand and provide signed informed consent; sufﬁcient
cognitive ability to complete questionnaires without assistance
as judged by clinicians and research staff; and ﬂuency (reading
and speaking) in English. Patients were recruited from a subset of
NCCN member institutions and community support agencies.
The NCCN is a not-for-proﬁt tax-exempt corporation that is an
alliance of National Cancer Institute–designated comprehensive
cancer centers. Patients were also recruited through members of
the Cancer Health Alliance of Metropolitan Chicago, a coalition of
four community support agencies serving the Chicago metropol-
itan area. These organizations were selected to provide patient
input from community-based practices to balance the preferen-
ces of patients from tertiary referral centers, such as NCCN sites.
Physician eligibility and recruitment
Physicians were recruited by e-mail sent to all NCCN member
institutions by NCCN headquarters staff. Physicians were eligible
to complete the disease-related/treatment-related survey if they
were in practice at any of the NCCN institutions and had at least
3 years’ experience treating a minimum of 100 patients with
advanced brain tumors. Physician input was solicited to deter-
mine which symptoms they considered to be disease related
versus treatment related.
Procedures
Patient survey
To avoid inﬂuencing patients’ thinking with any existing ques-
tionnaire content, they were ﬁrst asked in an open-ended inter-
view to “Think of the full range of your experience receiving drug
treatment for your illness. Please tell me what you think are the
most important symptoms or concerns to monitor when assess-
ing the value of drug treatment for your illness.” Patients were
then asked, “Please tell me on a scale of 0-10 (with 0 being not
important and 10 being extremely important) how important
each symptom or concern is to you.”
Patients were then asked to complete a 40-item symptom/
concern checklist, which included items from FACT-Br [15,25],
NCCN Symptom Index for Brain Tumor [18], and FACT-General
[12,26]. Patients were ﬁrst asked to select up to 10 symptoms or
concerns on the checklist that they felt were “the most important
symptoms or concerns to monitor when assessing the value of
drug treatment for brain tumor.” Of those symptoms/concerns
nominated as most important, patients were then asked to select
up to ﬁve as “the very most important.” Space was provided for
respondents to write in symptoms or concerns that were not
already listed. Four versions of each checklist were created to
control for response bias due to order effect. This symptom
checklist was identical to that administered to NCCN physicians
and nurses in a previous study [18].
Patients then completed FACT-Br, which consists of 27 items
from FACT-General, assessing physical well-being, functional
well-being, social/family well-being, and emotional well-being,
plus the brain tumor–speciﬁc subscale. These responses were
used in conducting the preliminary analyses of reliability and
validity described in the subsequent sections.
Physician survey
Physicians completed an online survey administered by Survey
Monkey. This survey, consisting of symptoms/concerns included
in the patient Checklist Coversheet, asked respondents to rate
each brain tumor symptom/concern on a ﬁve-point scale as to
Table 1 – Patient Information.
Age (y), mean  SD (range) 52.2  11.1
(30–79)
Sex, %
Male 66
Female 34
Race, %
White 90
African American 6
Others 4
Education, %
High school graduate or less 14
Some college 22
College 34
Advanced degree 30
Performance rating*(self-rated), %
Normal activities, no symptom 28
Some symptoms, no bed rest 38
Bed rest o50% of waking day 34
Performance rating* (physician rated), %
Normal activities, no symptom 17
Some symptom, no bed rest 60
Bed rest o50% of waking day 21
Bed rest 450% of waking day 2
EQ-5D questionnaire/mobility, %
No problems in walking about 54
Slight problems in walking about 18
Some problems in walking about 22
A lot of problems in walking about 6
EQ-5D questionnaire /self-care, %
No problems with self-care 80
Slight problems washing or dressing myself 12
Some problems washing or dressing myself 4
A lot of problems washing or dressing myself 2
Unable to wash or dress myself 2
EQ-5D questionnaire /usual activities, %
No problems with performing my usual
activities
34
Slight problems 32
Some problems 22
A lot of problems 12
EQ-5D questionnaire /pain or discomfort, %
No pain or discomfort 60
Slight pain or discomfort 22
Moderate pain or discomfort 14
A lot of pain or discomfort 2
Extreme pain or discomfort 2
EQ-5D questionnaire /anxiety or depression, %
Not anxious or depressed 46
Slightly anxious or depressed 38
Moderately anxious or depressed 10
Very anxious or depressed 4
Extremely anxious or depressed 2
Self-rated health status (0 ¼ Worst and 100 ¼
Best imaginable), mean  SD (range)
70.2  21.5
(5–100)
EQ-5D, EuroQol ﬁve-dimensional.
 Rated by using Eastern Cooperative Oncology Group Performance
Status Rating.
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ease related,” “too close to determine,” “predominantly a treat-
ment side effect,” or “exclusively a treatment side effect.”
Physicians were also provided the option of rating symptoms as
neither disease related nor treatment related.Analysis
The threshold for item retention was surpassing the “top 5”
endorsement frequency that would occur by chance. This was
calculated by dividing the allowable number of “very most
important symptoms” (N ¼ 5) by the total number of items in
the brain tumor checklist (N ¼ 40) and multiplying by the number
of patients (N ¼ 50). Items most frequently endorsed by patients
were compared with expert clinician responses obtained in our
previous work [18]. The samples (i.e., physicians, nurses, and
patients) were then pooled, and the item priority lists were
reviewed for appropriateness and redundancy by the study team.
Write-in items were also reviewed.
All the most frequent patient-endorsed items (cutoff score: 5/
40  50 ¼ 6.25; i.e., top 5 choices/40 items  50 patients) were
prioritized for inclusion in the ﬁnal symptom index. Items
generated from the open-ended question regarding the most
important symptoms or concerns were reviewed to ﬁll the
content gap in the original symptom index. Symptoms judged
by experts to be primarily disease related were included if 10% of
the patients reported it to be important. Symptoms judged by
experts to be primarily treatment related were included if they
were reported by more than 20% of the patients.
We then evaluated the internal consistency of the above-
selected items (criterion: Cronbach’s α 40.7; item-total correlations
40.3). Convergent validity of the symptom index was evaluated by
examining the associations between the symptom index and FACT-
Brain. This was accomplished by calculating Spearman correlation
coefﬁcients between symptom index scores with scores of FACT
scales. Symptom index scores were expected to correlate more
highly with other scales with which they should theoretically
correlate (e.g., FACT total scores, physical well-being, functional
well-being, and Trial Outcome Index) and are expected to correlate
to a lesser extent with scales from which they should differ (e.g.,
social/family well-being). We then evaluated how well the new
symptom index discriminated patients with different performance
status as deﬁned by the Eastern Co-operative Oncology Group
Performance Status Ratings. Preliminary validation analyses were
also performed with patient ratings of the ﬁve-level prototype
version of the EuroQol ﬁve-dimensional questionnaire [27].
From the physician survey results, we tabulated the ratings
for each symptom and created two subscales: one consisting of
symptoms and concerns that are “exclusively” or “predomi-
nantly” disease-related and the other consisting of symptoms
and concerns that are “exclusively” or “predominantly”
treatment-related. Items predominately related to general func-
tioning and well-being were categorized in a third subscale, the
General Function and Well-Being subscale.Results
Sample
Fifty patients with brain tumor were recruited from Duke Uni-
versity Medical Center (n ¼ 17), Mofﬁtt Cancer Center (n ¼ 15),
Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research
Center (n ¼ 8), Northwestern Memorial Hospital (n ¼ 6), Cancer
Health Alliance of Metropolitan Chicago (n ¼ 3), and NorthShore
University HealthSystem (formerly, Evanston Northwestern
Healthcare; n ¼ 1). Patient information is summarized in
Table 1. The average age of these patients was 52.2  11.1 years,
and the sample was well educated (64% at least college graduate).
Men comprised 66% of the sample, and 90% of the sample was
white. All patients were diagnosed with either stage III or IV brain
tumor, with no other cancer diagnosis within the last 5 years, and
received at least two cycles of chemotherapy or noncyclical
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completed the survey by using the paper-and-pencil version in
clinic, 2% (n ¼ 1) via mail, and 8% (n ¼ 5) via face-to-face
interview. Eastern Co-operative Oncology Group Performance
Status Ratings, assessed by both patient and provider report,
reﬂected a group that was experiencing some interference in
functioning (Table 1). Patients reported their current health
status at an average of 70.2 in a 0 to 100 scale (0 ¼ Worst
imaginable health state; 100 ¼ Best imaginable health state).
Of the sample of 10 physicians who were surveyed about brain
tumor, average age was 52  8.4 years and 90% were men. Of
them, 80% had experiences treating advanced brain tumor
patients for more than 10 years and 80% had treated more than
500 patients with advanced brain tumors.
Survey Results
Of 40 symptoms/concerns in the checklist, 12 met the cutoff
(endorsed by more than six patients) and 11 were borderline (sixTable 2 – Frequency of spontaneous patient-reported sym
Rank No. of
responses
(%)
Example of symptom/co
1 19 (49) Fatigue
Fatigue (short-term and long-term); Fatig
2 16 (41) Effectiveness (or treatment uncertainty)
Will chemotherapy work; Effectiveness of
of tumor
Options
What are other options if chemotherapy
through treatment
3 15 (38) Nausea
4 11 (28) Appetite
Appetite suppression; Loss of (or lack of; l
liquids was a problem
5 8 (21) Seizures
Effect of seizures on quality of life; Contr
5 8 (21) Cognition
Ability to think; Loss of attention; Thinki
6 7 (18) Effect on senses
Loss of hearing; Loss of taste; Less taste; I
Increased sensitivity to cold on your te
7 5 (13) Gross motor functions
Motor skills affected (by chemotherapy);
7 5 (13) Fine motor functions
Handwriting ability; Ability to use hands;
7 5 (13) Increased anxiety
Anxiety (over weight loss); Anxiety, fear
7 5 (13) Memory loss
Memory loss; Short-term memory loss
7 5 (13) Weakness
Weakness; Muscle weakness; Weak
7 5 (13) Hair loss
8 4 (10) Sleep disruption
Sleep disruption; Proper rest; Difﬁculty fa
8 4 (10) Weight loss
8 4 (10) Pain
Pain; Severe pain
8 4 (10) Financial concerns
Financial concern; Insurance, and tricare
8 4 (10) Constipation
Note. Only those symptoms that were endorsed by more than 10% of thsymptoms/concerns endorsed by six patients and ﬁve endorsed
by ﬁve patients). Of the 12 that met the cutoff criterion, 1 item,
“Worry about dying,” was not included in the ﬁnal index because
it has previously been found to be highly correlated with a more
relevant and acceptably phrased expression included in the index
(“I worry my condition will get worse”).
In terms of open-ended questions, responses were grouped
into 57 categories and 18 of them were reported by at least 10% of
the patients. Most endorsed was fatigue (49%), followed by treat-
ment effectiveness (41%), nausea (38%), change in appetite (28%),
seizures (21%), and cognitive skills (21%). Table 2 shows the exact
wording used by patients and the importance rated by patients.
Among these 18 symptoms/concerns, 5 of them were not covered
by the original 40-symptom checklist: appetite (28%), hair loss
(13%), weight loss (10%), ﬁnancial concerns (10%), and constipa-
tion (10%). Items were selected from existing FACIT items to
address weight loss and appetite. “Hair loss” and “constipation”
were considered treatment-related side effects and may change
when the therapies change. Because patients frequently listedptoms ratings.
ncern stated by patients Mean
importance
rating (0–10)
6.2
ue (slow paced); Lack of energy
9.2
treatment; Effectiveness of drug; Recurrence
does not work? Treatment plan and options
7.9
7.9
ess) appetite; Problems with eating; Drinking
7.8
ol our seizures
9.3
ng goes blank; Reading; Mental fogginess
8.6
ncreased sensitivity to smells; Double vision;
eth in Temodar
9.6
Ability to move around; Walking
9
Difﬁculty cutting food; Writing
8.4
8.2
7.4
5.2
9.8
lling asleep
7.3
7
7
, explanation of coverage
4.8
e patients are included here.
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“I am bothered by side effects.” This item was selected instead of
speciﬁc symptoms so that the instrument would remain relevant
across different and new therapies that may have differing side-
effect proﬁles. “Financial concerns” was related to neither treat-
ment nor disease. Although this is a critical and increasing issue,
we did not write an additional item to address this concern
because it does not ﬁt the traditional deﬁnition of advanced
cancer symptom. In addition, “I feel fatigued” was added to
reﬂect the fact that energy/fatigue was rated so much more
frequently than the other symptoms. This strategy enables the
index to capture extra weight for fatigue in the total score. These
results are summarized in Table 3.
The ﬁnal NCCN/FACT-Br Symptom Index (NFBrSI-24) con-
sisted of 24 items (listed in Table 4), of which 21 are already
included in FACT-Br. These 24 items were further divided into
three subscales: 1) Disease Related Symptoms, which includes 12
physical symptoms and 5 emotional symptoms; 2) TreatmentTable 3 – Symptom/concerns selection.
Symptoms from the 40-item
symptom/concern checklist
Met
cutoff*
Patient
rated in
top 5 (%)
Excl
Lack of energy (fatigue) X 44
Frustration that I cannot do things I
used to
X 22
Being able to enjoy life X 20
Nausea X 18
Seizures (convulsions) X 18
Trouble with coordination X 18
Worry that my condition will get
worse
X 18
A change in my personality X 16
Being able to ﬁnd the right word(s) to
say what I mean
X 16
Being able to remember new things X 16
Being able to concentrate X 14
Being able to sleep well 12
Being content with the quality of my
life right now
12
Headaches 10
Fear of having a seizure (convulsion) 8
Losing hope in the ﬁght against my
illness
8
Needing help in caring for myself
(bathing, dressing, eating, etc.)
8
Because of my physical condition,
having trouble meeting the needs
of my family
6
Difﬁculty expressing my thoughts 6
Weakness in my arms or legs 4
Followings are the symptoms
proposed by patients and met the
inclusion criteria
I am bothered by side effects of
treatment
Losing weight
I have a good appetite
I feel fatigued
 Cutoff ¼ endorsed by more than six patients (top 5 choices/40 items 
† No symptom/concern in this table was endorsed as “exclusively treatmSide Effects (5 items); and 3) Function/Well-Being (2 items).
Acceptable internal consistency was found for the full-length
version of the Symptom Index, Disease Related Symptom sub-
scale, and Function/Well-Being subscale, with alpha values of
0.84, 0.79, and 0.89, respectively. The Treatment Side Effect
subscale had an alpha value of 0.65. Of the four items that were
suggested by patients in the open-ended interview, three were
not included in the original FACT-Br. Because participants com-
pleted the original FACT-Br to determine initial validity of the
NFBrSI-24, there were no data available on these three newly
generated items for this analysis. Thus, summary scores used for
the rest of the initial validation analyses were prorated by using
the standard FACIT measurement system approach for missing
item responses [13]. The NFBrSI and its subscales signiﬁcantly
differentiated patients with different levels of functional status
as rated by using the Eastern Co-operative Oncology Group
Performance Status Ratings: F2,47 ¼ 8.21, P ¼ 0.0008; F2,47 ¼ 7.18,
P ¼ 0.0019; F2,47 ¼ 7.77, P ¼ 0.0012; and F2,47 ¼ 3.20, P ¼ 0.0498 forPhysician rated (%)
Disease-related Too close to
determine
Treatment
related†
usively Predominantly predominantly
30 20 50
90 10
70 30
10 10 80
70 30
30 70
70 30
50 40 10
80 20
30 50 20
60 40
40 40 20
50 50
40 60
80 20
10 90
20 80
10 40 50
70 20 10
60 30 10
50 patients ¼ 6.25).
ent related” by physicians.
Table 4 – A side-by-side comparison of the items
included on the newly revised NCCN/FACT-Brain
Symptom Index (NFBrSI) and FACT-Brain.
Revised NCCN/FACT-BrSI items (divided
by subscale)
Item on
FACT-Brain?
Disease Related Symptom-Physical (NFBrSI-DRS-P)
An10-I get headaches Yes
Br21-I have trouble with coordination Yes
Br2-I have had seizures (convulsions) Yes
Br14-I need help in caring for myself
(bathing, dressing, eating, etc.)
Yes
Br20-I have weakness in my arms or legs Yes
C2-I am losing weight No
GP3-Because of my physical condition, I
have trouble meeting the needs of my
family
Yes
Br9-I have difﬁculty expressing my
thoughts
Yes
GF5-I am sleeping well Yes
Br1-I am able to concentrate Yes
Br3-I can remember new things Yes
Br8-I am able to ﬁnd the right word(s) to say
what I mean
Yes
Disease Related Symptom-Emotional
(NFBrSI-DRS-E)
Br10-I am bothered by the change in my
personality
Yes
GE6-I worry that my condition will get
worse
Yes
Br5-I am afraid of having a seizure
(convulsion)
Yes
Br4-I get frustrated that I cannot do things I
used to
Yes
GE3-I am losing hope in the ﬁght against
my illness
Yes
Treatment Side Effect (NFBrSI-TSE)
GP1-I have a lack of energy Yes
GP2-I have nausea Yes
GP5-I am bothered by side effects of
treatment
Yes
HI7-I feel fatigued No
C6-I have a good appetite No
Function/Well-Being (NFBrSI-F/WB)
GF3-I am able to enjoy life Yes
GF7-I am content with my quality of life
right now
Yes
Note. Eleven FACT-Brain additional concern items are not included
in the revised NCCN/FACT-BrSI. They are as follows: 1) I have
trouble with my eyesight; 2) I feel independent; 3) I have trouble
hearing; 4) I am able to make decisions and take responsibility; 5) I
am bothered by the drop in my contribution to the family; 6) I am
able to put my thoughts together; 7) I am able to put my thoughts
into action; 8) I am able to read like I used to; 9) I am able to write
like I used to; 10) I am able to drive a vehicle (my car, truck, etc.);
11) I have trouble feeling sensations in my arms, hands, or legs.
FACT, Functional Assessment of Cancer Therapy; NCCN, National
Comprehensive Cancer Network.
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Side Effects, and NFBrSI-Function/Well-Being, respectively. We
also examined the association of scores on the NFBrSI with FACT-
Br and its subscales. After removal of overlapping items, the total
NFBrSI was most highly correlated with FACT-General functional
well-being (ρ ¼ 0.59), physical well-being (ρ ¼ 0.57), and braincancer–speciﬁc concerns (ρ ¼ 0.50, all P o 0.001). Moderate
correlations were found with social well-being (ρ ¼ 0.40) and
emotional well-being (ρ ¼ 0.35, all P o 0.05).Discussion
Advanced brain tumor can be a devastating diagnosis, often
associated with morbidity and mortality. Symptoms experienced
by patients with brain tumors vary depending on clinical factors
such as tumor location, histology, and extent of disease. Findings
that the symptoms experienced by patients predicted disease
progression—in addition to their effect on HRQOL—suggest that
symptoms may provide an additional marker of patient response
[2,10]. It follows that a symptom index speciﬁcally for patients
with advanced brain tumors has both clinical and research
importance, especially when it includes symptoms rated as high
priority by both patients and clinicians. In this article, we report
the most recent step in a multistep effort to develop a methodo-
logically rigorous index incorporating both the patients’ and the
clinicians’ perspectives. Symptoms or concerns included in this
index were informed by the top ﬁve symptom priorities endorsed
by patients, as well as previously collected symptom priorities
endorsed by expert clinicians. The resulting NFBrSI-24 captured
symptoms addressed in the literature, such as fatigue, headache,
pain, vomiting, nausea, neurologic and mental status symptoms
(e.g., dizziness), seizure, and symptom distress [28,29]. In initial
validation analyses, the NFBrSI-24 had acceptable internal con-
sistency and convergent validity and discriminated patients with
different levels of functional performance. The NFBrSI-24 was
developed by using US patients. Although we believe that
patients from different countries share similar symptoms, vali-
dation of the NFBrSI-24 to patients from other countries is
recommended to ensure the measurement equivalence between
cultures/languages.
Recent initiatives have placed a greater importance on includ-
ing the patient’s voice in health care, and in cancer care
speciﬁcally, in an effort to engender more patient-centered care.
Research demonstrating that patient-reported outcomes can
improve adverse event data collection has provided further
evidence of the beneﬁts of patient-centered care [6,30,31]. Con-
sequently, it is increasingly common for adult cancer clinical
trials to incorporate patient-reported outcomes assessment along
with clinician-reported assessments [32–34]. As the ﬁrst symp-
tom index speciﬁc to advanced brain tumors that includes
symptoms considered high priority by patients and clinicians,
the NFBrSI-24 shows promise as a new tool to assess patient
response to treatment in clinical research and clinical settings.
Moreover, its methodologically rigorous, multistep development
process also satisﬁes regulatory requirements, such as the FDA’s
Oncologic Drug Advisory Committee Quality of Life Subcommit-
tee’s statement that pharmaceutical company claims of
improved HRQOL outcomes should be speciﬁc to the HRQOL
domain measured and should reﬂect the patient’s perspective
[23]. Although other instruments such as M.D. Anderson Symp-
tom Inventory for Brain Tumor are available for measuring
symptoms experienced by patients with brain tumor, items were
not generated speciﬁc to patients with advanced brain tumor. In
addition, M.D. Anderson Symptom Inventory for Brain Tumor
used a 10-point rating and a 24-hour time frame while the
NFBrSI-24 used a 5-point intensity rating scale and a 7-day time
frame. Our previous study [35] indicated that ratings of a 0 to 10
rating scale did not distribute equally on a measurement con-
tinuum and therefore should be not used directly to measure
changes over time. There is no deﬁnite conclusion about the best
time frame to measure symptoms. We chose a 7-day time frame
over a 24-hour time frame with the consideration that some
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 2 – 6 968symptoms might not occur during the last 24 hours. A longer
time frame would help capture patients’ real experiences. Thus,
the NFBrSI-24 is a viable option for capturing patient-reported
outcomes in clinical trials evaluating treatment outcomes among
individuals with advanced brain tumors.
Different methods are available to generate concerns from
patients such as the ranking method. We tested our method
against a ranking method in pilot studies before this work. We
learned through observation with patients that when presented
with lists as long as 50 items, they have difﬁculty with ranking
and they tend to rank the earlier items more highly because of an
order effect. We then experimented with counterbalancing the
order to control for the order effect, but this tends to drive up
sample size. While conducting these pilot studies, we learned
that patients preferred a simple identiﬁcation task whereby they
can nominate the 10 most important symptoms or concerns, and
then having narrowed the set to 10, further drop that number to
5. We ﬁnd that this produces a robust set of ﬁve priority concerns
per patient, which can then be ranked by summing the number of
patients who nominate each symptom or concern.
When considering the NFBrSI-24 for use in clinical research or
the clinical setting, several questions may arise. First, clinicians and
researchers who have previously used FACT-Br to assess patient-
reported outcomes in individuals with brain tumors may wonder
whether it is possible to convert FACT-Br scores into NFBrSI-24
scores. Because of the four new symptoms not included on FACT-Br,
it is not possible to directly calculate NFBrSI-24 scores from FACT-Br;
however, a closely comparable score can be calculated by prorating
FACT-Br data according to the following formula: 24  [(sum of
NFBrSI-24 item responses)/(number of NFBrSI-24 items completed)] if
more than 50% of the 24 items (i.e., more than 12 of the 20 in FACT-
Br) are completed [36]. In addition, potential users of the NFBrSI-24
maywonder when this measure would be preferable to its precursor,
FACT-Br. We recommend using the NFBrSI-24 to assess symptoms
identiﬁed as most important when treating advanced disease. In
contrast, FACT-Br would be a preferable option when the goal is the
assessment of more multidimensional aspects of HRQOL, or assess-
ment of HRQOL in individuals with early-stage disease [15,37].
The NFBrSI-24 is the ﬁrst measure speciﬁcally designed to
assess speciﬁc symptoms and concerns of patients with
advanced brain tumors on the basis of importance ratings from
both patients and clinicians. The index will beneﬁt from ongoing
enhancements. Speciﬁcally, research should further develop the
psychometric properties of the NFBrSI-24. This may include a
closer examination of the Treatment Side Effects scale, whose
reliability was less adequate when compared with the other
scales or the measure as a whole. Cognitive debrieﬁng procedures
may yield a better understanding of this scale and identify
potential areas for revision to improve reliability. In addition,
given the cross-sectional nature of this initial validation study,
future longitudinal research should examine the responsiveness
of the NFBrSI-24 to longitudinal clinical change. Such a study,
using the full set of 24 items, would supplement the preliminary
validation results presented here. Future research using the
NFBrSI-24 in samples with greater sociodemographic and clinical
heterogeneity will also advance the generalizability of the meas-
ure. We did not screen patients by using formal neuropsycho-
logical testing results. Future study may be conducted to evaluate
whether neuropsychological testing results affect the reliability
and validity for patients reporting their own symptoms.
Another important goal of future research is to ensure that
the NFBrSI-24’s content matches potential changes in clinical
care and treatment options such as the newly developed particle
therapy (e.g., proton therapy and carbon ion therapy) [38]. This
initial validation study applied a broad deﬁnition of “advanced
brain tumors” (stage III or IV) to create a measure representative
of the range of symptoms across the continuum of advancedbrain tumors. The item “I am bothered by side effects” was
selected in place of two speciﬁc side effects, in part to anticipate
a future in which the nature of side effects will change as new
treatments emerge. We suggest reviewing the reliability and
validity of the NFBrSI-24 Treatment Side Effect subscale periodi-
cally to facilitate potential revisions to reﬂect substantive treat-
ment changes.
In conclusion, this is the ﬁrst study to report on the develop-
ment and initial validation of the NFBrSI-24, an index of the
symptoms in advanced brain tumors perceived as most impor-
tant by both patients and clinicians. The NFBrSI-24 further
improves upon existing measures of brain tumor symptoms
through better satisfaction of regulatory requirements for meas-
ure development. The initial ﬁndings suggest acceptable reliabil-
ity and validity, indicating that the NFBrSI-24 is a promising brief
assessment of high-priority advanced brain tumor symptoms for
use in research and clinical settings.
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